Skip to Main Content

Try STAT+ TODAY

patents

Most Read

Pharmalot Ed Silverman

STAT Plus: Solicitor general recommends Supreme Court shouldn’t review an Amgen patent case

Pharmalot Ed Silverman

STAT Plus: Federal patent initiatives could cause ‘headwinds’ for drugmakers and their broad filings

Pharmalot Ed Silverman

STAT Plus: ViiV will make it easier for generic companies to copy its HIV prevention shot, but it’s not clear when

Pharmalot Ed Silverman

STAT Plus: A battle is brewing between a senator and a nonprofit over pharma patenting practices

Pharmalot Ed Silverman

STAT Plus: Oxfam wants the SEC to investigate Moderna for ‘misleading’ investors about its Covid patent dispute with NIH

First Opinion Tahir Amin and Priti Krishtel

Solving the U.S. drug pricing crisis starts with a crucial confirmation hearing

Opinions+ Andrei Iancu and David Kappos

STAT Plus: Why does the FDA want to stop improving medicines via patent ‘areas of concern’?

First Opinion Lyrissa Lidsky

Patent reform is needed to protect patients’ access to lifesaving drugs

All Coverage

Pharmalot Ed Silverman

STAT Plus: Dutch group sues AbbVie for human rights violations stemming from Humira pricing

Politics John Wilkerson

STAT Plus: Senate panel passes drug patent reforms, but not without dissent

advertisement

Pharmalot Ed Silverman

STAT Plus: U.S. delays backing for patent waivers on Covid-19 therapies and diagnostics

Pharmalot Ed Silverman

STAT Plus: European Commission says preliminary findings indicate Teva violated antitrust rules

Pharmalot Ed Silverman

STAT Plus: Alnylam sues Pfizer and Moderna for patent infringement in development of Covid-19 vaccines

Pharmalot Ed Silverman

STAT Plus: Moderna will never enforce Covid-19 vaccine patents in poor countries

Pharmalot Ed Silverman

STAT Plus: AbbVie asks the U.S. International Trade Commission to investigate Alvotech’s plans for a biosimilar Humira

Pharmalot Ed Silverman

STAT Plus: Facing intense criticism, Moderna pauses bitter dispute with the NIH over Covid-19 vaccine patents

Pharmalot Ed Silverman

STAT Plus: U.S. lawmakers accuse patent office of weakening challenges and allowing drug prices to rise

Pharmalot Ed Silverman

STAT Plus: Advocates urge Biden to name patent office director that could transform drug pricing

Pharmalot Ed Silverman

STAT Plus: Moderna vows not to enforce Covid-19 patents, but advocates say IP should be given to WHO

Pharmalot Ed Silverman

STAT Plus: Consumer groups and unions urge FTC to block AbbVie and Allergan merger

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Judge appears to back push for opioid settlement; the CRISPR patent fight lives on

First Opinion Othman Laraki

Proposed patent legislation would block research, stifle innovation, and harm patients

Pharmalot Ed Silverman

STAT Plus: FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

Pharmalot Ed Silverman

STAT Plus: Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: NAFTA deal may hinge on patent protections for drugs; House committee goes after Sacklers

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Allergan depression drug fails three trials; Vertex CEO appears before Parliament

Pharmalot Ed Silverman

STAT Plus: Bristol-Myers faces growing opposition to its Celgene deal. Here’s what the wags are saying

First Opinion Peter Kolchinsky and Jessica Sagers

We need a Public Domain Day to highlight when drugs go off patent

Pharmalot Ed Silverman

STAT Plus: AbbVie must fork over Humira documents after judge slams a ‘nonsense’ argument

Pharma Ed Silverman and Matthew Herper

STAT Plus: Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Drug makers to raise prices in January; Novartis names a new oncology chief, again

Pharmalot Ed Silverman

STAT Plus: Trump administration report would preclude reclaiming patents as a way to lower drug prices